Abstract
Apart from new anti-tuberculosis drug development, another approach for tuberculosis (TB) treatment optimization is to derive maximum benefit from current agents. However, the dosage of current anti-TB drug regimens has never been optimized according to the exposure-effect relationships of each drug. The objective of this article is to review the latest pharmacokinetic, pharmacodynamic, experimental, and clinical data concerning the use of higher doses of first-line anti-TB drugs to improve the efficacy of pulmonary tuberculosis treatment. Exposure-effect relationships have been described for all first-line anti-TB agents. There is convincing evidence that patients would benefit from higher rifamycin exposure. This could be achieved by using higher daily doses of rifampin, or more frequent dosing of rifapentine. The dose-dependent activity of pyrazinamide observed in hollow-fiber and animal models suggests that higher doses of pyrazimamide might be more efficacious, but the tolerability of such higher doses needs to be investigated in humans. It is likely that higher doses of ethambutol would be associated with higher antibacterial effect, but the dose-related ocular toxicity of the drug precludes such practice. For isoniazid, dose individualization is required to optimize patient care. The use of higher than standard doses of isoniazid in fast acetylators should result in greater early bactericidal activity. To conclude, the use of higher doses for some of the firstline anti-TB agents has definite potential for shortening or improving TB treatment.
Keywords: Pulmonary tuberculosis, anti-tuberculosis drugs, dosage design, pharmacokinetics, pharmacodynamics.
Current Pharmaceutical Design
Title:The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy
Volume: 20 Issue: 39
Author(s): Sylvain Goutelle, Laurent Bourguignon, Pascal Maire, Roger W. Jelliffe and Michael N. Neely
Affiliation:
Keywords: Pulmonary tuberculosis, anti-tuberculosis drugs, dosage design, pharmacokinetics, pharmacodynamics.
Abstract: Apart from new anti-tuberculosis drug development, another approach for tuberculosis (TB) treatment optimization is to derive maximum benefit from current agents. However, the dosage of current anti-TB drug regimens has never been optimized according to the exposure-effect relationships of each drug. The objective of this article is to review the latest pharmacokinetic, pharmacodynamic, experimental, and clinical data concerning the use of higher doses of first-line anti-TB drugs to improve the efficacy of pulmonary tuberculosis treatment. Exposure-effect relationships have been described for all first-line anti-TB agents. There is convincing evidence that patients would benefit from higher rifamycin exposure. This could be achieved by using higher daily doses of rifampin, or more frequent dosing of rifapentine. The dose-dependent activity of pyrazinamide observed in hollow-fiber and animal models suggests that higher doses of pyrazimamide might be more efficacious, but the tolerability of such higher doses needs to be investigated in humans. It is likely that higher doses of ethambutol would be associated with higher antibacterial effect, but the dose-related ocular toxicity of the drug precludes such practice. For isoniazid, dose individualization is required to optimize patient care. The use of higher than standard doses of isoniazid in fast acetylators should result in greater early bactericidal activity. To conclude, the use of higher doses for some of the firstline anti-TB agents has definite potential for shortening or improving TB treatment.
Export Options
About this article
Cite this article as:
Goutelle Sylvain, Bourguignon Laurent, Maire Pascal, Jelliffe W. Roger and Neely N. Michael, The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy, Current Pharmaceutical Design 2014; 20 (39) . https://dx.doi.org/10.2174/1381612820666140901215544
DOI https://dx.doi.org/10.2174/1381612820666140901215544 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Peptide Nucleic Acids as Antibacterial Agents
Current Medicinal Chemistry New Trends in Development of Antimycobacterial Compounds
Infectious Disorders - Drug Targets Molecular Modeling Databases: A New Way in the Search of Protein Targets for Drug Development
Current Bioinformatics Designing Type II Topoisomerase Inhibitors: A Molecular Modeling Approach
Current Topics in Medicinal Chemistry An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design Modern Approach to Medical Diagnostics - the Use of Separation Techniques in Microorganisms Detection
Current Medicinal Chemistry HIV-Specific T Cells: Strategies for Fighting a Moving Target
Current HIV Research Anti-Tuberculosis
Current Bioactive Compounds Current Trends in Enzyme Inhibition and Docking Analysis in Drug Design-Part -II
Current Topics in Medicinal Chemistry Purine Metabolism in Mycobacterium tuberculosis as a Target for Drug Development
Current Pharmaceutical Design Current Technology in the Discovery and Development of Novel Antibacterials
Current Drug Targets Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets Recent Advances in the Rational Drug Design Based on Multi-target Ligands
Current Medicinal Chemistry Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update
Current Topics in Medicinal Chemistry Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Classification of Small GTPases with Hybrid Protein Features and Advanced Machine Learning Techniques
Current Bioinformatics Despite an Extensive Sequence Analysis Identification of Functional Candidates Amongst Hypothetical Proteins of Neisseria gonorrhoeae
Letters in Drug Design & Discovery Occurrence of DAT1 (VNTR) Polymorphism in Individuals with HIV Infection
Current Pharmacogenomics and Personalized Medicine The Role of Vitamin D in Prevention and Treatment of Infection
Inflammation & Allergy - Drug Targets (Discontinued) Contemporary Progress in the Synthesis and Reaction of 2-Arylbenzothiazole: A Review
Current Organic Chemistry